Additional treatments affecting APN and downstream activators include Os-pep, a novel nonapeptide APN mimetic, which binds to APN receptors [101] and activin, which may be a potential therapeutic target for reduction of amyloidogenic proteins during AD progression [117]. The gene discussed is ANPEP; the disease is Alzheimer disease.